At the time of writing, Cytokinetics Inc [CYTK] stock is trading at $65.42, up 1.27%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CYTK shares have gain 6.60% over the last week, with a monthly amount drifted -0.38%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cytokinetics Inc [NASDAQ: CYTK] stock has seen the most recent analyst activity on December 18, 2025, when Goldman upgraded its rating to a Buy but kept the price target unchanged to $95 for it. On April 24, 2025, Barclays initiated with an Overweight rating and assigned a price target of $55 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $86 on February 07, 2025. Stifel initiated its recommendation with a Buy and recommended $80 as its price target on January 22, 2025. RBC Capital Mkts started tracking with an Outperform rating for this stock on November 08, 2024, and assigned it a price target of $80. In a note dated August 13, 2024, Goldman downgraded a Neutral rating on this stock and revised its target price from $85 to $60.
For the past year, the stock price of Cytokinetics Inc fluctuated between $29.31 and $70.98. Currently, Wall Street analysts expect the stock to reach $88.73 within the next 12 months. Cytokinetics Inc [NASDAQ: CYTK] shares were valued at $65.42 at the most recent close of the market. An investor can expect a potential return of 35.63% based on the average CYTK price forecast.
Analyzing the CYTK fundamentals
According to Cytokinetics Inc [NASDAQ:CYTK], the company’s sales were 87.21M for trailing twelve months, which represents an 318.14% jump. Gross Profit Margin for this corporation currently stands at -1.28% with Operating Profit Margin at -6.57%, Pretax Profit Margin comes in at -8.62%, and Net Profit Margin reading is -8.62%. To continue investigating profitability, this company’s Return on Assets is posted at -0.52, Equity is 2.33 and Total Capital is -0.44. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -2.3.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 64.39 points at the first support level, and at 63.36 for the second support level. However, for the 1st resistance point, the stock is sitting at 66.52, and for the 2nd resistance point, it is at 67.62.
Ratios To Look Out For
It is important to note that Cytokinetics Inc [NASDAQ:CYTK] has a current ratio of 6.88. As well, the Quick Ratio is 6.88, while the Cash Ratio is 1.59. Considering the valuation of this stock, the price to sales ratio is 91.72.
Transactions by insiders
Recent insider trading involved Callos Andrew, EVP, Chief Commercial Officer, that happened on Jan 05 ’26 when 15000.0 shares were sold. EVP, Chief Commercial Officer, Callos Andrew completed a deal on Jan 02 ’26 to sell 1798.0 shares. Meanwhile, Officer ANDREW CALLOS bought 59570.0 shares on Jan 02 ’26.
